Solano-Genesta M, Tarin-Arzaga LC, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, Martínez-Hernández RA, Cuervo-Sierra J, Gómez-Almaguer D

Language: Spanish
References: 10
Page: 188-192
PDF size: 60.76 Kb.

ABSTRACT

Background: Historically allogeneic stem cell transplantation has been limited to young patients due to the morbid-mortality associated to myeloablative conditioning. In recent years elderly patients have become eligible to reduced intensity conditioning allogeneic bone marrow transplantation.
Material and methods: The present report summarizes our experience in a cohort of 30 elderly patients (age 55-71, median 59 years) with hematologic malignancies as well as bone marrow failure, treated with reduced intensity conditioning allogeneic stem cell transplantation: “The Mexican method”.
Results: The median neutrophil and platelets recovery was 15 and 13 days respectively. Overall Survival (OS) was 50% with Relapse Free Survival (RFS) of 36.6% and the advance disease group had a RFS of only 9%. Relapse was observed in 43%.
Conclusions: Transplant related mortality was 16% and aGVHD presented in 20% of patients and cGVHD in 16%. RIC allogeneic stem cell transplantation can be safely applied in elderly patients and may become an important tool of treatment without age limit.

REFERENCES

1. Alyea EP, Kim HT, Ho V, Cutler C, et al. Comparative outcome of nonmyeloablative and myeloablative allogenic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005;105:1810-1814.

2. Sorror ML, Maris MB, Storb R, Baron F, et al. Hematopoietic cell transplantation (HCT) specific comorbidity index: a new tool for risk assessment before allogenic HCT. Blood 2005;106:2912-2919.

3. Falda M, Busca A, Baldi I, Mordini N, et al. Nonmyeloablative allogenic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial. Am J Hematol 2007;82:863-866.

4. Shimoni A, Kröger N, Zabelina T, Ayuk F, et al. Hematopoietic stem cell transplantation from unrelated donors in elderly patients (age › 55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia 2005;19:7-12.

5. Tsirigotis P, Bitan RO, Resnick IB, Samuel S, et al. A non myeloablative conditioning regimen in allogenic stem cell transplantation from related and unrelated donors in elderly patients. Haematologica 2006;91:852-855.

6. Koreth J, Aldridge J, Kim HT, Alyea EP 3rd, et al. Reduced intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant 2010;16:792-800.

7. Shapira MY, Resnick IB, Bitan M, Ackerstein A, et al. Low transplant related mortality with allogenic stem cell transplantation in elderly patients. Bone Marrow Transplantation 2004;34:155-159.

8. Gomez-Almaguer D, Vela-Ojeda J, Jaime-Pérez JC, Gutierrez-Aguirre CH, et al. Allografting in patients with severe, refractory aplastic anemia using peripherals blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience. Am J Hematol 2006;81:157-161.

9. Ruiz-Argüelles GJ, Morales-Toquero A, López-Martínez B, Tarín-Arzaga L-del-C, et al. Bloodless (transfusion free) hematopoietic stem cell transplants: The Mexican experience. Bone Marrow Transplantation 2005;36:715-720.

10. Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-DelgadoGJ, Tarin-Arzaga LC. Ocho años de experiencia con el “Método mexicano” en la realización de transplantes de células hematopoyéticas alogenitas. Gaceta Med Mex 2007;143:231-235.